Physician profile
Miguel Sierra-Hoffman
NPI 1265472906
$237,960.28
in general payments reported to CMS, 2019-2025
37 companies · $24K in 2025
The $24K reported for 2025 was more than what 96% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82K · 2020: $18K · 2021: $8,548 · 2022: $29K · 2023: $57K · 2024: $20K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $72K · Travel and Lodging: $9,719 · Food and Beverage: $9,267 · Honoraria: $7,451 · Education: $1,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $72,457.61 |
| Travel and Lodging | $9,719.18 |
| Food and Beverage | $9,267.37 |
| Honoraria | $7,451.00 |
| Education | $1,354.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $55,642.41 | 2019-2025 | Kimyrsa, Rezzayo, Vabomere |
| Merck Sharp & Dohme LLC | $43,134.71 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Ferring Pharmaceuticals INC. | $36,126.40 | 2020-2025 | Rebyota |
| Allergan, INC. | $32,273.30 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $24,546.05 | 2020-2025 | Xerava, Zevtera, Giapreza |
| Abbvie INC. | $22,070.38 | 2021-2025 | Avycaz, Dalvance, Teflaro |
| Insmed, INC. | $9,374.02 | 2019-2025 | Arikayce, Brinsupri |
| Paratek Pharmaceuticals, INC. | $5,990.15 | 2019-2025 | Nuzyra |
| Tetraphase Pharmaceuticals, INC. | $5,340.60 | 2019-2020 | |
| Shionogi INC | $577.49 | 2020-2025 | Fetroja |
| Electromed, INC. | $456.41 | 2021-2025 | Smartvest |
| Astellas Pharma US INC | $402.42 | 2019-2023 | Cresemba |
| Gilead Sciences, INC. | $369.75 | 2019-2025 | Epclusa |
| Baxter Healthcare | $242.12 | 2023-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System, Fluid Systems - Drug Delivery Systems |
| Actelion Pharmaceuticals US, INC. | $211.47 | 2024 | Opsumit, Uptravi |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $180.24 | 2019-2022 | |
| Mylan Specialty L.P. | $118.10 | 2020-2021 | |
| Viatris Specialty LLC | $107.44 | 2025 | Yupelri |
| Astrazeneca Pharmaceuticals Lp | $96.19 | 2022 | |
| Musculoskeletal Transplant Foundation INC. | $85.96 | 2020 | |
| Chiesi USA, INC. | $78.64 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $73.93 | 2022 | |
| Tactile Systems Technology INC | $71.14 | 2024-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Invivyd INC | $50.37 | 2025 | Pemgarda |
| Aimmune Therapeutics, INC. | $50.14 | 2024 | |
| Philips North America LLC | $47.79 | 2021-2024 | (Ak6) Vest Therapy |
| Corcept Therapeutics | $38.48 | 2024 | Korlym |
| Mallinckrodt Enterprises LLC | $31.89 | 2019 | |
| Theratechnologies INC. | $31.17 | 2020 | |
| Smith+Nephew, INC. | $21.30 | 2019 | |
| Biomerieux INC | $19.74 | 2025 | Biofire Spotfire Control Station |
| Alexion Pharmaceuticals, INC. | $19.59 | 2021 | |
| Vyera Pharmaceuticals, LLC | $18.85 | 2020 | |
| Cormedix INC. | $17.88 | 2025 | Defencath |
| T2 Biosystems, INC. | $16.24 | 2019 | |
| Mayne Pharma Commercial LLC | $15.08 | 2020 | |
| Emd Serono, INC. | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miguel Sierra-Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.